Skin Pathology Lab
Our group studies the molecular mechanism at the basis of immune-mediated cutaneous disease as Psoriasis, a chronic inflammatory, hyperproliferative skin disease, using the approach of epigenetic analysis and gene regulation technics to map key genes responsible of the onset of the skin hyperproliferation.
Main research areas
Epigenetic roadmap of keratinocytes and skin infiltrating lymphocytes in atopic dermatitis
In order to depict the epigenetic landscape of normal keratinocytes, that describe the enhancer repertoire of this type of cells discriminating between constitutive, poised and latent enhancer region, we perform ChIPseq analysis of Primary human epidermal keratinocytes with antibody against two key histone markers. The hypothesis is that drugs treatment could modulate the transcription activity of keratinocyte by changing the status of active enhancers or of latent enhancers. Simila experiments will be performed on T cells belonging to the inflammatory microenvironment of atopic skin. (IMMUNIVERSE project)
New strategies for diagnostic, therapeutic and clinical care in Skin immunological diseases
The aim of this project is to develop patentable methods based on genetic markers and functional assays to predict the response to biologics in psoriasis. Patients genotype will be correlated to clinical response to biological drugs to identify predictive markers and to characterize functional responses of T-lymphocytes to psoriasis autoantigen.
Optoacoustic and ultrasound technology for dermatology application
WINTHER EU HORIZON2020 project is driven by leading dermatologists (Prof. Costanzo and Prof. Biedermann in TUM Munich) and market leader SMEs in optoacoustic and ultrasound technology (iThera, Rayfos, Sonaxis), to design and prototype a handheld, portable, scalable, label-free F-RSOM device for point-of care dermatology applications, a photonic & ultrasound technologies that will improve the use of RSOM technology in dermatology suites for fast diagnosis and therapy monitoring in both skin disease and cardiovascular/metabolic diseases. RSOM can go beyond the abilities of current optical or optoacoustic devices and offer a paradigm shift in dermatology imaging.